CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a ...
Infinity Pharmaceuticals (OTC:INFI) has reportedly filed for bankruptcy in the wake of a terminated merger deal with MEI Pharma. The biotech company filed for Chapter 11 bankruptcy protection in a ...
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Infinity Pharmaceuticals(INFI) is on sale; its stock plunged 70% to a new 52-week low To save on operational ...
Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) ...
SAN DIEGO, CA. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback